Clinical Trials Browser

Phase 1/2 × OTHER × raltitrexed × Clear all

NCT05426811 2022-06-29

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms